Indirect Cost of Ischemic Heart Disease to EmployersByChristine J. Guico-Pabia, MD, MBA,James F. Murray, PhD,Steven M. Teutsch, MD, MPH,Albert I. Wertheimer, PhD, MBA,Marc L. Berger, MDJanuary 1st 2001
Disenrollment from Medicare HMOsByKathleen Tiede Call, PhD,Bryan E. Dowd, PhD,Roger Feldman, PhD,Nicole Lurie, MD, MSPH,Marshall A. McBean, MD, MSc,Matthew Maciejewski, PhDJanuary 1st 2001
A Comparison of Abciximab Use in MCO and Non-MCO PopulationsByMaureen J. Lage, PhD,Beth L. Barber, PhD,Mohan Bala, PhD,Daniel E. Ball, MBA,Lee Bowman, PhDJanuary 1st 2001
Drugs and the Elderly, Part 2: Strategies for Improving Prescribing in a Managed Care EnvironmentByMark H. Beers, MD,Robert W. Baran, PharmD,Kathleen Frenia, PharmDJanuary 1st 2001
Ambulatory Drug Utilization Review: Opportunities for Improved Prescription Drug UseByAlan Lyles, ScD, MPH, RPh,Betsy Sleath, PhD, RPh,Thomas R. Fulda,Theodore M. Collins, RPhJanuary 1st 2001
Can Administrative Database Studies Inform Medication Use Policy Decisions? An Application of Occam's RazorByLee C. Vermeulen, RPh, MS,Paul A. Windisch, PharmDJanuary 1st 2001
Is the Healthcare Workforce a Barrier to Cost Containment?ByMelanie C. Dreher, PhD, RNJanuary 1st 2001
